• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

异构1,2 - 二氨基环己烷铂(II)配合物在DNA中产生的加合物的表征

Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexaneplatinum(II) complexes.

作者信息

Jennerwein M M, Eastman A, Khokhar A

机构信息

Eppley Institute for Research in Cancer, University of Nebraska Medical Center, Omaha 68105.

出版信息

Chem Biol Interact. 1989;70(1-2):39-49. doi: 10.1016/0009-2797(89)90061-6.

DOI:10.1016/0009-2797(89)90061-6
PMID:2736676
Abstract

The cancer chemotherapeutic drug cis-diamminedichloroplatinum(II) (cis-DDP) is active as a result of its bifunctional reactions with DNA. Many other platinum complexes also have therapeutic activity. Of current interest are complexes containing 1,2-diaminocyclohexane (DACH). The DACH ligand exists in three isomeric forms with reported differences in therapeutic activity in the order R,R greater than S,S greater than R,S-DACH-Pt. The reaction of the sulphate form of each of these three isomers with DNA has been characterized as a possible explanation for the apparent differences in antitumor activity. These reactions have been characterized by platinating pure DNA followed by enzyme digestion, HPLC separation and analysis by atomic absorption and nuclear magnetic resonance. The spectrum of adducts produced was similar for each isomer and similar to that reported for cis-DDP with adduction at d(GpG), d(ApG) and (dG)2. The R,S-isomer additionally demonstrated isomeric adducts at d(GpG) and d(ApG). The kinetics of formation of the various adducts was the same for each isomer; total platination of DNA was complete in 15 min as were bifunctional adducts at d(GpG) and (dG)2. However, rearrangement to bifunctional adducts took several hours in the case of adducts at d(ApG) sequences. These results did not provide a reason for the different activities of the isomers. It is suggested that the interaction of these adducts with metabolic processes such as DNA repair might explain these differences.

摘要

癌症化疗药物顺二氨二氯铂(II)(顺铂)因其与DNA的双功能反应而具有活性。许多其他铂配合物也具有治疗活性。目前人们感兴趣的是含有1,2 - 二氨基环己烷(DACH)的配合物。DACH配体以三种异构体形式存在,据报道其治疗活性存在差异,顺序为R,R大于S,S大于R,S - DACH - Pt。这三种异构体的硫酸盐形式与DNA的反应已得到表征,以此作为解释其抗肿瘤活性明显差异的一种可能原因。这些反应通过用铂处理纯DNA,然后进行酶消化、高效液相色谱分离以及原子吸收和核磁共振分析来表征。每种异构体产生的加合物谱相似,且与报道的顺铂在d(GpG)、d(ApG)和(dG)2处的加合物谱相似。R,S - 异构体在d(GpG)和d(ApG)处还显示出异构体加合物。每种异构体形成各种加合物的动力学相同;DNA的完全铂化在15分钟内完成,d(GpG)和(dG)2处的双功能加合物也是如此。然而,对于d(ApG)序列处的加合物,重排为双功能加合物需要数小时。这些结果并未为异构体的不同活性提供原因。有人认为这些加合物与DNA修复等代谢过程的相互作用可能解释了这些差异。

相似文献

1
Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexaneplatinum(II) complexes.异构1,2 - 二氨基环己烷铂(II)配合物在DNA中产生的加合物的表征
Chem Biol Interact. 1989;70(1-2):39-49. doi: 10.1016/0009-2797(89)90061-6.
2
Characterization of bifunctional adducts produced in DNA by trans-diamminedichloroplatinum(II).反式二氯二氨合铂(II)在DNA中产生的双功能加合物的表征
Chem Biol Interact. 1988;67(1-2):71-80. doi: 10.1016/0009-2797(88)90087-7.
3
Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum (IV) complexes mediated by axial and equatorial ligands.轴向和赤道配体介导的1,2-二氨基环己烷铂(IV)配合物的细胞毒性和细胞药理学调节
Cancer Res. 1993 Oct 1;53(19):4567-72.
4
Reaction of (1R,2S,3S)-3-methylcyclohexanediamineplatinum(II) with DNA: isolation and characterization of the platinum-nucleotide adducts by means of HPLC and NMR spectroscopy.(1R,2S,3S)-3-甲基环己二胺铂(II)与DNA的反应:通过高效液相色谱法和核磁共振光谱法对铂-核苷酸加合物进行分离与表征
Chem Pharm Bull (Tokyo). 1995 Feb;43(2):183-8. doi: 10.1248/cpb.43.183.
5
RNA polymerases react differently at d(ApG) and d(GpG) adducts in DNA modified by cis-diamminedichloroplatinum(II).RNA聚合酶对顺式二氯二氨合铂(II)修饰的DNA中的d(ApG)和d(GpG)加合物反应不同。
Biochemistry. 1992 Feb 25;31(7):1904-8. doi: 10.1021/bi00122a002.
6
Characterization of a DNA damage-recognition protein from mammalian cells that binds specifically to intrastrand d(GpG) and d(ApG) DNA adducts of the anticancer drug cisplatin.对一种来自哺乳动物细胞的DNA损伤识别蛋白的特性研究,该蛋白能特异性结合抗癌药物顺铂的链内d(GpG)和d(ApG) DNA加合物。
Biochemistry. 1990 Jun 19;29(24):5872-80. doi: 10.1021/bi00476a032.
7
Replication inhibition and translesion synthesis on templates containing site-specifically placed cis-diamminedichloroplatinum(II) DNA adducts.在含有位点特异性放置的顺二氯二氨铂(II)DNA加合物的模板上的复制抑制和跨损伤合成。
Biochemistry. 1992 Apr 28;31(16):3975-90. doi: 10.1021/bi00131a013.
8
Trans-diammineplatinum(II): what makes it different from cis-DDP? Coordination chemistry of a neglected relative of cisplatin and its interaction with nucleic acids.反式二氨合铂(II):它与顺铂有何不同?顺铂一个被忽视的同类物的配位化学及其与核酸的相互作用。
Met Ions Biol Syst. 1996;33:105-41.
9
Role of carrier ligand in platinum resistance of human carcinoma cell lines.载体配体在人癌细胞系铂耐药中的作用。
Cancer Res. 1993 Feb 15;53(4):799-805.
10
Differential antitumor activity and toxicity of isomeric 1,2-diaminocyclohexane platinum (II) complexes.异构1,2-二氨基环己烷铂(II)配合物的抗肿瘤活性和毒性差异
J Cancer Res Clin Oncol. 1993;120(1-2):12-6. doi: 10.1007/BF01200718.

引用本文的文献

1
A comparative analysis of the mutagenicity of platinum-containing chemotherapeutic agents reveals direct and indirect mutagenic mechanisms.含铂化疗药物致突变性的比较分析揭示了直接和间接的致突变机制。
Mutagenesis. 2021 Apr 28;36(1):75-86. doi: 10.1093/mutage/geab005.
2
Repurposing bioactive compounds for treating multidrug-resistant pathogens.生物活性化合物再利用治疗多药耐药病原体。
J Med Microbiol. 2020 Jun;69(6):881-894. doi: 10.1099/jmm.0.001172.
3
GLUT1-mediated selective tumor targeting with fluorine containing platinum(II) glycoconjugates.
利用含氟铂(II)糖缀合物通过葡萄糖转运蛋白1介导的肿瘤选择性靶向
Oncotarget. 2017 Jun 13;8(24):39476-39496. doi: 10.18632/oncotarget.17073.
4
Oxaliplatin and its enantiomer induce different condensation dynamics of single DNA molecules.奥沙利铂及其对映体诱导单链 DNA 分子不同的凝聚动力学。
PLoS One. 2013 Aug 12;8(8):e71556. doi: 10.1371/journal.pone.0071556. eCollection 2013.
5
Debio 0507 primarily forms diaminocyclohexane-Pt-d(GpG) and -d(ApG) DNA adducts in HCT116 cells.德博 0507 主要在 HCT116 细胞中形成二胺环戊烷-Pt-d(GpG)和-d(ApG)DNA 加合物。
Cancer Chemother Pharmacol. 2012 Mar;69(3):665-77. doi: 10.1007/s00280-011-1744-3. Epub 2011 Oct 4.
6
Flanking bases influence the nature of DNA distortion by platinum 1,2-intrastrand (GG) cross-links.侧翼碱基影响铂 1,2-同型(GG)交联导致的 DNA 扭曲性质。
PLoS One. 2011;6(8):e23582. doi: 10.1371/journal.pone.0023582. Epub 2011 Aug 10.
7
Towards biomarker-dependent individualized chemotherapy: exploring cell-specific differences in oxaliplatin-DNA adduct distribution using accelerator mass spectrometry.迈向基于生物标志物的个体化化疗:利用加速器质谱法探索奥沙利铂 - DNA加合物分布中的细胞特异性差异。
Bioorg Med Chem Lett. 2010 Apr 15;20(8):2448-51. doi: 10.1016/j.bmcl.2010.03.020. Epub 2010 Mar 7.
8
Inhibition of transcription by platinum antitumor compounds.铂类抗肿瘤化合物对转录的抑制作用。
Metallomics. 2009;1(4):280-91. doi: 10.1039/b907567d.
9
Structural basis for the sequence-dependent effects of platinum-DNA adducts.铂-DNA加合物序列依赖性效应的结构基础。
Nucleic Acids Res. 2009 May;37(8):2434-48. doi: 10.1093/nar/gkp029. Epub 2009 Mar 2.
10
Molecular dynamic simulations of cisplatin- and oxaliplatin-d(GG) intrastand cross-links reveal differences in their conformational dynamics.顺铂和奥沙利铂与d(GG)链内交联的分子动力学模拟揭示了它们构象动力学的差异。
J Mol Biol. 2007 Nov 9;373(5):1123-40. doi: 10.1016/j.jmb.2007.07.079. Epub 2007 Aug 23.